

Utilization Management Updates

Effective July 1, 2018, the following Utilization Management updates will apply to RxClaim Book A environments. A maintenance medication update letter will be sent to all current utilizers 60 days before the effective date. The member letters will be sent on or before May 1, 2018.

OptumRx Focused UM Program

OptumRx clients in the OptumRx Focused UM Program will receive the following updates.

Updates To Existing OptumRx Focused Step Therapy With Quantity Limits Programs

Therapeutic Category	Current Step 2 Drugs (Requires trial of Step 1)	Current Step 1 Drugs	Updates Effective July 1, 2018
Gastrointestinal: Opioid-Induced Constipation	Movantik	Amitiza	Step 2 Drugs: Movantik Step 1 Drugs: generic lactulose or polyethylene glycol AND Amitiza

Additional Utilization Management Updates

Effective July 1, 2018, the following Utilization Management updates will apply to clients in the RxClaim Book A environments. A maintenance medication update letter will be sent to all current utilizers 60 days before the effective date.

STEP Step Therapy

Program Type	UM Type	Target Drugs	Program Rationale
Opioid-Induced Constipation: Select	ST	Movantik	Update to existing UM program. The existing ST on Movantik will be updated to mirror the other ST edits within the class. Will require trial of generic lactulose or polyethylene glycol AND Amitiza.

PA Prior Authorization

Program Type	UM Type	Target Drugs	Program Rationale
Anti-Infectives: Standard	PA	Albenza	New UM program. A PA will be added to ensure appropriate use in this costly medication.
Gastroprotective Agents: Standard	PA w/QL	Duexis	New UM program. A PA will be added to ensure appropriate use in this costly medication.
Metabolic Agents: Standard	PA	Nityr Orfadin	New UM Program. A PA will be added to ensure appropriate use.

QL Quantity Limit

Please refer to the OptumRx Quantity Limit Change Details table below for specific quantity limits.

Program Type	UM Type	Target Drugs	Program Rationale
ADHD Agents: Standard	QL	Adderall (amphetamine-dextroamphetamine) 30 mg tablet	Update to existing UM program. The QL for Adderall 30 mg tablets will be decreased to help ensure the maximum FDA-approved dose is not exceeded.
Analgesics (opioid): Standard	QL	butorphanol nasal spray	New UM program. To be consistent with how short-acting opioids are managed, a QL will be added to butorphanol nasal spray as part of the Opioid Risk Management Program.
	QL	levorphanol tablets	New UM program To be consistent with how short-acting opioids are managed, a QL will be added to levorphanol tablets as part of the Opioid Risk Management Program.
	QL	Ultracet (tramadol-acetaminophen) tablets	New UM program To be consistent with how short-acting opioids are managed, a QL will be added to Ultracet tablets as part of the Opioid Risk Management Program.
	QL	Ultram (tramadol) tablets	New UM program To be consistent with how short-acting opioids are managed, a QL will be added to Ultram tablets as part of the Opioid Risk Management Program.
Antidepressants: Standard	QL	Wellbutrin (bupropion) SR tablets	Update to existing UM program. The QL for Wellbutrin SR will be decreased to help ensure the maximum dosing frequency is not exceeded.
Hyper-cholesterolemia: Standard	QL	Flolipid (simvastatin) suspension	New UM program. To help ensure safe and appropriate dosing, a QL will be added to Flolipid suspension.

OptumRx Quantity Limit Change Details

Drug	Current Quantity Limit	New Quantity Limit
Adderall (amphetamine-dextroamphetamine) 30 mg	3 tablets per day	2 tablets per day
butorphanol nasal spray	None	1 bottle per prescription, 2 prescriptions per 60 days
Flolipid (simvastatin) 20 mg/5 mL	None	10 mL per day
Flolipid (simvastatin) 40 mg/5 mL	None	5 mL per day
levorphanol	None	<p>Patients new to therapy: 3 tablets per day, no more than a 7 day supply per prescription, 2 prescriptions per 60 days</p> <p>Patients with prior therapy history: 6 tablets per day, 2 prescriptions per 60 days</p>
Ultracet (tramadol-acetaminophen)	None	<p>Patients new to therapy: 8 tablets per day, no more than a 7 day supply per prescription, 2 prescriptions per 60 days</p> <p>Patients with prior therapy history: 8 tablets per day, 2 prescriptions per 60 days</p>
Ultram (tramadol)	None	<p>Patients new to therapy: 8 tablets per day, no more than a 7 day supply per prescription, 2 prescriptions per 60 days</p> <p>Patients with prior therapy history: 8 tablets per day, 2 prescriptions per 60 days</p>
Wellbutrin (bupropion) SR	3 tablets per day	2 tablets per day

OptumRx UM Program Retirements

Program Type	UM Type	Targeted Drugs	Rationale
Select	ST	Duexis	There was significant utilization despite a step therapy program. The ST program will be retired and replaced with a new PA program in an effort to better manage utilization of this costly product.



OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

© 2018 Optum, Inc. All rights reserved. ORX7258-UM_180701 72952-022018